cp 115953 has been researched along with amsacrine in 7 studies
*Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent. [MeSH]
*Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent. [MeSH]
| Studies (cp 115953) | Trials (cp 115953) | Recent Studies (post-2010) (cp 115953) | Studies (amsacrine) | Trials (amsacrine) | Recent Studies (post-2010) (amsacrine) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 1,293 | 127 | 120 |
| Protein | Taxonomy | cp 115953 (IC50) | amsacrine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 5 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.43 | |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | 5.47 | |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | 5 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 1.88 | |
| Aldehyde oxidase | Homo sapiens (human) | 3.2 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2095 | |
| Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | 6.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldous, SC; Coughlin, SA; Dorff, PH; Gruett, MD; Lesher, GY; Rake, JB; Reuman, M; Singh, B; Wentland, MP | 1 |
| Chung, IK; Gootz, TD; McGuirk, PR; Muller, MT; Spitzner, JR | 1 |
| Corbett, AH; Elsea, SH; Osheroff, N; Westergaard, M | 1 |
| Corbett, AH; Osheroff, N; Robinson, MJ | 1 |
| Corbett, AH; Hong, D; Osheroff, N | 1 |
| Burden, DA; Elsea, SH; Lomenick, JP; Osheroff, N; Westergaard, M | 1 |
| Dong, J; Nitiss, JL; Walker, J | 1 |
1 review(s) available for cp 115953 and amsacrine
| Article | Year |
|---|---|
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Genistein; Humans; Isoflavones; Models, Structural; Quinolones; Topoisomerase II Inhibitors | 1994 |
6 other study(ies) available for cp 115953 and amsacrine
| Article | Year |
|---|---|
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; HeLa Cells; Humans; Leukemia P388; Mice; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Topics: Amsacrine; Anti-Infective Agents; Base Sequence; DNA; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Humans; Hydrolysis; Molecular Sequence Data; Quinolones; Teniposide; Topoisomerase II Inhibitors | 1995 |
Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Topics: Adenosine Triphosphate; Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; Cell Nucleus; DNA Topoisomerases, Type II; DNA, Bacterial; Drosophila melanogaster; Escherichia coli; Etoposide; Fluoroquinolones; Genistein; Hydrolysis; Isoflavones; Novobiocin; Plasmids; Quercetin; Quinolones; Topoisomerase II Inhibitors | 1993 |
Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Topics: Amsacrine; Animals; Anti-Infective Agents; Binding Sites; Cell Line; Cell Nucleus; DNA; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Drug Interactions; Etoposide; Fluoroquinolones; Genistein; Growth Inhibitors; Isoflavones; Kinetics; Novobiocin; Protein Binding; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; CHO Cells; Ciprofloxacin; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Electrophoresis, Agar Gel; Enzyme Activation; Etoposide; Fluoroquinolones; Genistein; Isoflavones; Kinetics; Molecular Structure; Quinolones | 1997 |
A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.
Topics: Amsacrine; Anti-Infective Agents; Binding Sites; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Enzyme Inhibitors; Eukaryotic Cells; Fluoroquinolones; Intercalating Agents; Models, Molecular; Mutation; Protein Structure, Tertiary; Saccharomyces cerevisiae; Topoisomerase II Inhibitors | 2000 |